Analyst downgrades typically lead to a negative short-term reaction in the stock market as they suggest a less favorable outlook for the company. The substantial cut in the price target from $8 to $4.5 by a major financial institution like B of A Securities could significantly undermine investor confidence in GoodRx, leading to a potential decrease in its stock price.